Xenon Pharmaceuticals Inc. (XENE)Healthcare | Biotechnology | Burnaby, Canada | NasdaqGM
59.70 USD
+1.27
(2.174%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 59.50 -0.20 (-0.200%) ⇩ (April 17, 2026, 5:41 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:12 p.m. EDT
Despite distressing fundamentals characterized by negative earnings, high cash burn, and low revenue, XENE is exhibiting strong speculative momentum driven by positive epilepsy trial data and a massive upcoming equity offering. The options flow confirms a 'smart money' positioning targeting a move toward the $70–$75 range before year-end, turning this into a momentum play despite the invalidity of traditional valuation metrics. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.159356 |
| MSTL | 0.167369 |
| AutoARIMA | 0.168916 |
| AutoETS | 0.169426 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 163.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.049 |
| Excess Kurtosis | -1.79 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.366 |
| Revenue per Share | 0.095 |
| Market Cap | 5,697,001,472 |
| Forward P/E | -12.62 |
| Beta | 0.75 |
| Website | https://www.xenon-pharma.com |
As of April 18, 2026, 11:12 p.m. EDT: Options activity reveals a distinct bullish skew. Call volume and Open Interest are heavily concentrated at strikes 70 and 75 for July expiration, with significant 'New Flow' at the $60 ATM strike in the near term. Put activity is sparse and primarily limited to lower strikes ($50) compared to the depth of call positioning, suggesting a bullish price/target expectation close to $65-$70 within the next two months. Implied volatility for calls is relatively contained (0.51-0.61 ATM) compared to the elevated 0.77 ATM IV for puts, indicating market pricing of downside protection is more expensive than upside speculation at this moment.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.72046113 |
| Address1 | 200-3650 Gilmore Way |
| All Time High | 63.95 |
| All Time Low | 2.1 |
| Ask | 76.16 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 869,450 |
| Average Daily Volume3 Month | 1,368,372 |
| Average Volume | 1,368,372 |
| Average Volume10Days | 869,450 |
| Beta | 0.745 |
| Bid | 42.64 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 7.271 |
| City | Burnaby |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 59.7 |
| Current Ratio | 13.415 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 59.82 |
| Day Low | 58.6483 |
| Debt To Equity | 1.366 |
| Display Name | Xenon Pharmaceuticals |
| Earnings Call Timestamp End | 1,762,205,400 |
| Earnings Call Timestamp Start | 1,762,205,400 |
| Earnings Timestamp | 1,772,139,600 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -370,527,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.944 |
| Enterprise To Revenue | 590.069 |
| Enterprise Value | 4,425,519,616 |
| Eps Current Year | -4.82655 |
| Eps Forward | -4.73106 |
| Eps Trailing Twelve Months | -4.36 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 51.0193 |
| Fifty Day Average Change | 8.680702 |
| Fifty Day Average Change Percent | 0.17014547 |
| Fifty Two Week Change Percent | 72.04611 |
| Fifty Two Week High | 63.95 |
| Fifty Two Week High Change | -4.25 |
| Fifty Two Week High Change Percent | -0.06645817 |
| Fifty Two Week Low | 28.19 |
| Fifty Two Week Low Change | 31.51 |
| Fifty Two Week Low Change Percent | 1.1177722 |
| Fifty Two Week Range | 28.19 - 63.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,415,197,800,000 |
| Float Shares | 78,362,782 |
| Forward Eps | -4.73106 |
| Forward P E | -12.618736 |
| Free Cashflow | -175,082,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 358 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -293,438,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00115 |
| Held Percent Institutions | 0.95317 |
| Implied Shares Outstanding | 95,427,159 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. |
| Long Name | Xenon Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 5,697,001,472 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_565718 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -345,910,016 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,695,092,849 |
| Number Of Analyst Opinions | 19 |
| Open | 59.47 |
| Operating Cashflow | -279,118,016 |
| Operating Margins | -49.742672 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 604 484 3300 |
| Post Market Change | -0.20000076 |
| Post Market Change Percent | -0.33500963 |
| Post Market Price | 59.5 |
| Post Market Time | 1,776,462,115 |
| Previous Close | 58.43 |
| Price Eps Current Year | -12.369083 |
| Price Hint | 2 |
| Price To Book | 8.2107 |
| Price To Sales Trailing12 Months | 759.6002 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.167 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 1.27 |
| Regular Market Change Percent | 2.17354 |
| Regular Market Day High | 59.82 |
| Regular Market Day Low | 58.6483 |
| Regular Market Day Range | 58.6483 - 59.82 |
| Regular Market Open | 59.47 |
| Regular Market Previous Close | 58.43 |
| Regular Market Price | 59.7 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 844,098 |
| Return On Assets | -0.32581002 |
| Return On Equity | -0.51757 |
| Revenue Per Share | 0.095 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 95,427,159 |
| Shares Percent Shares Out | 0.0508 |
| Shares Short | 4,851,044 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 5,533,096 |
| Short Name | Xenon Pharmaceuticals Inc. |
| Short Percent Of Float | 0.0555 |
| Short Ratio | 2.13 |
| Source Interval | 15 |
| State | BC |
| Symbol | XENE |
| Target High Price | 100.0 |
| Target Low Price | 58.58 |
| Target Mean Price | 79.24105 |
| Target Median Price | 80.0 |
| Total Cash | 548,886,016 |
| Total Cash Per Share | 6.598 |
| Total Debt | 7,944,000 |
| Total Revenue | 7,500,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.36 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 42.090473 |
| Two Hundred Day Average Change | 17.609528 |
| Two Hundred Day Average Change Percent | 0.41837323 |
| Type Disp | Equity |
| Volume | 844,098 |
| Website | https://www.xenon-pharma.com |
| Zip | V5G 4W8 |